2022
Long-Term Outcomes of Randomized Controlled Trials Comparing Percutaneous Left Atrial Appendage Closure to Oral Anticoagulation for Nonvalvular Atrial Fibrillation: A Meta-Analysis
Madhavan M, Howard J, Brener M, Der Nigoghossian C, Chen S, Makkar R, Osmancik P, Reddy V, Holmes D, Stone G, Leon M, Ahmad Y. Long-Term Outcomes of Randomized Controlled Trials Comparing Percutaneous Left Atrial Appendage Closure to Oral Anticoagulation for Nonvalvular Atrial Fibrillation: A Meta-Analysis. Structural Heart 2022, 7: 100096. PMID: 37275318, PMCID: PMC10236864, DOI: 10.1016/j.shj.2022.100096.Peer-Reviewed Original ResearchLeft atrial appendage closurePercutaneous left atrial appendage closureRandomized clinical trialsNonvalvular atrial fibrillationOral anticoagulationAtrial appendage closureAtrial fibrillationNonprocedural bleedingCause mortalityAppendage closureHazard ratioHemorrhagic strokeClinical trialsLong-term oral anticoagulationReduced long-term riskLarge-scale clinical trialsIndividual clinical endpointsPrespecified primary endpointCochrane Central RegisterStandard of careNew trial dataSignificant differencesLong-term riskStroke prophylaxisPrimary endpoint
2021
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials
Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M, Shahim B, Leon MB, Bangalore S, Stone GW, Ahmad Y. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal 2021, 42: 2643-2654. PMID: 34002202, PMCID: PMC8282325, DOI: 10.1093/eurheartj/ehab280.Peer-Reviewed Original ResearchConceptsThin-strut drug-eluting stentsUltrathin-strut drug-eluting stentsTarget lesion failureDrug-eluting stentsStent thrombosisMyocardial infarctionCardiac deathCause mortalityCD-TLRRisk of TLFSystematic reviewPre-specified primary endpointRisk of MIRevascularization of patientsWeighted mean followTarget lesion revascularizationPercutaneous coronary interventionStandard of careNew trial dataCause deathLesion revascularizationEligible trialsLesion failureMean followPrimary endpoint